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Abstract Proteins encoded by non-oncogenic adenovirus type 5
and oncogenic adenovirus type 12 differentially affect expression
of a number of cellular genes. We have used cDNA micro array
analysis to identify a cellular gene that is expressed in Ad12- but
not in Ad5-transformed cells. This cellular gene was found to
be the gene encoding follistatin-related protein, a TGF-L in-
ducible gene. Consistently, a constitutive factor binding to Smad
binding elements was found in adenovirus type 12-transformed
cells. ß 2000 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Non-immortal rodent cells and a limited number of non-
immortal human cell types can be transformed by human
adenoviruses (Ad) [1]. The transforming activity of these vi-
ruses maps to the early region 1 (E1) of the viral genome,
which encodes the E1A and E1B proteins [2]. A large number
of di¡erent Ad serotypes exist, which are subdivided on the
basis of their capacity to induce tumors in hamsters. Group A
consists of highly oncogenic viruses (e.g. Ad12), whereas
group C consists of non-oncogenic viruses (e.g. Ad5) [3]. All
Ad serotypes are able to transform rodent cells, but only cells
transformed by the oncogenic Ad serotypes are oncogenic in
syngenic animals. Studies on the di¡erences between cells
transformed by Ad5 or Ad12 have led to the identi¢cation
of di¡erentially expressed cellular genes in the two types of
transformed cells, which has contributed to our understanding
of oncogenic transformation. The downregulation of MHC
class I [4] and the transporters associated with antigen pre-
sentation (TAPs) [5,6] in Ad12-transformed cells might be
particularly important with respect to the oncogenicity. Due
to the lack of MHC class I membrane expression, viral pro-
teins can not be presented to the immune system, which
causes these cells to escape immune surveillance by cytotoxic
T cells [7].
So far, the mechanism by which Ad5E1 and Ad12E1 lead
to di¡erences in gene expression remains unclear, indicating
that undiscovered di¡erentially expressed genes must exist
that contribute to the downregulation of the MHC I and
TAP genes. The recent availability of arrayed ESTs on nylon
¢lters opens a new possibility to screen for di¡erences in gene
expression between Ad5- and Ad12-transformed cells. This
system enables the identi¢cation of di¡erentially regulated
genes that are hard to be found by hypothesis-driven strat-
egies. Using this system, we found a novel di¡erentially regu-
lated gene, which encodes the follistatin-related protein
(FRP). Previously, FRP was found to be a target for TGF-
L and in accordance with this ¢nding, a constitutive factor
binding to Smad binding elements (SBE) was found in
Ad12-transformed cells.
2. Materials and methods
2.1. Materials
EST W52072 was obtained from Incyte Genomics (St. Louis, MO,
USA). ESTs AI690397 and AI866922 were obtained from the Re-
source Center/Primary Database of the German Human Genome
Project, Max Planck Institute (Berlin, Germany). TGF-L1 was ob-
tained from RpD systems (Minneapolis, MN, USA).
2.2. Cell lines and culture
Human embryo cells from retina (HER), kidney (HEK) and lung
(HEL) cells were cultured in F-15 medium supplemented with 10 or
15% FCS and antibiotics. For EMSA experiments, cells were grown
on Dulbecco’s modi¢ed Eagle’s medium (DMEM) supplemented with
10% FCS and antibiotics. Furthermore, 1 mM pyruvate, 15 mM glu-
cose, 4.1 mM L-glutamine and 8.2 WM biotin were added. Tissue
culture media and sera were purchased from Gibco BRL (Gaithers-
burg, MD, USA). All tissue culture-plastics were obtained from
Greiner (Solingen, Germany).
2.3. Comparative cDNA micro array analysis
cDNA micro array analysis was performed using the human I ver-
sion 1.2 Gene Discovery Array from Incyte Genomics (St. Louis, MO,
USA) according to the instructions of the manufacturer. This array
consists of 18 376 ESTs arrayed on nylon ¢lters. [K-33P]dCTP-labeled
complex cDNAs were prepared from mRNA of exponentially grow-
ing Ad5-transformed HER clone 1 and Ad12-transformed HER clone
7 cells. These two cDNA pools were used to hybridize two identical
arrays. Signals were quanti¢ed by phosphorimager and subsequently,
these arrays were stripped and hybridized with the other cDNA
pool.
2.4. RNA extraction and Northern blotting
Total RNA was isolated from exponentially growing cells as de-
scribed previously [8]. 10 Wg of total RNA from exponentially growing
cells was size-fractionated on a 1% agarose/2.2 M formaldehyde gel by
electrophoresis and transferred to Hybond ¢lters (Amersham Pharma-
cia Biotech, Little Chalfont, Buckinghamshire, UK). Filters were hy-
0014-5793 / 00 / $20.00 ß 2000 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 0 ) 0 2 3 3 9 - 5
*Corresponding author. Fax: (31)-71-527 6284.
E-mail: zantema@lumc.nl
FEBS 24431 27-12-00
FEBS 24431 FEBS Letters 487 (2000) 151^155
bridized with the indicated probes. A human multiple-tissue Northern
blot (7780-1; Clontech, Palo Alto, CA, USA) was hybridized accord-
ing to the instructions of the manufacturer. RNA was isolated from
Wilms tumors and corresponding normal kidney tissue as described
previously [9].
2.5. Electrophoretic mobility shift assay (EMSA)
Preparation of nuclear extracts, binding reactions and electropho-
resis were essentially performed as described elsewhere [8]. Where
indicated, the cells were treated with 7 ng/ml TGF-L1 for 30 min in
DMEM supplemented with 0.3% FCS and antibiotics. Nuclear
extracts were incubated with a double-stranded oligonucleotide con-
taining three SBE. The sequence of the double-stranded SBE oligo-
nucleotide was 5P-TCGAGAGCCAGACAAGGAGCCAGACAAG-
GAGCCAG-3P and the complementary strand 5P-GTGTCTGGCTC-
CTTGTCTGGCTCCTTGTCTGGCTC-3P. This double-stranded oli-
gonucleotide was labeled by ¢lling in recessed 3P ends with [K-32P]-
dATP and [K-32P]dCTP using the Klenow fragment of DNA poly-
merase I. Binding reactions containing 10 Wg of nuclear extracts and
25 fmol of labeled oligonucleotides were performed for 30 min at
room temperature in 50 Wl of binding bu¡er. For competition experi-
ments, a 33-fold molar excess of cold competitor probe was added.
The sequence of the double-stranded SBE mutant oligonucleotide
used in these competition experiments was 5P-TCGAGAGCTACA-
TAAGGAGCTACATAAGGAGCTAC-3P and the complementary
strand 5P-GTATGTAGCTCCTTATGTAGCTCCTTATGTAGCTC-
3P, made completely double-stranded by ¢lling in the recessed 3P
ends using the Klenow fragment of DNA polymerase I. After electro-
phoresis, the 5% polyacrylamide gels were dried and exposed to X-ray
¢lms.
Fig. 1. Di¡erential expression of the gene corresponding to EST58 in Ad5 and Ad12-transformed cells. A: Gene expression pro¢ling of Ad5-
and Ad12-transformed cells using cDNA micro arrays. Shown is a part of the gene expression pro¢le of Ad5-transformed cells. B: Detail of
cDNA micro arrays. Di¡erentially expressed genes were detected by comparing the intensity of signals between both micro arrays. Shown is a
small fragment of the two micro arrays. Arrows indicate a gene (spotted twice) that is more highly expressed in Ad5 cells than in Ad12 cells.
C: Di¡erential expression of the gene corresponding to EST58 in Ad5- and Ad12-transformed HER cells. Equal amounts of total RNA from
exponentially growing HER cells was size-fractionated by electrophoresis and transferred to Hybond ¢lters. Filters were hybridized with
[K-32P]dCTP labeled 0.8 kb NotI^EcoRI EST58 fragment. Indicated are the 28S and 18S ribosomal RNA bands. Control hybridizations were
performed using the PstI fragment of the rat GAPDH cDNA. D: Downregulation of the gene corresponding to EST58 in Ad5-transformed
HEL- and HEK cells. Northern blot analysis was performed as described under C.
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3. Results and discussion
3.1. Comparative cDNA micro array analysis of Ad5- and
Ad12-transformed cells
To study di¡erences in gene expression between Ad5- and
Ad12-transformed cells, partial gene expression pro¢les were
obtained using the human I version 1.2 Gene Discovery Array
from Incyte Genomics. Fig. 1A shows a part of the gene
expression pro¢le of Ad5-transformed HER clone 1 cells. In
these hybridizations, 11 genes were consistently found to be
di¡erentially expressed in the Ad5-and Ad12-transformed
HER cells. One example of a gene that is expressed more
highly in Ad5-transformed cells than in Ad12-transformed
cells is shown in Fig. 1B. The corresponding ESTs of these
11 genes were obtained and used as probes in Northern blot
analysis. Five out of the 11 genes turned out to be indeed
di¡erentially expressed in these Ad5- and Ad12-transformed
cell lines. Equal expression was found for two genes, no signal
could be detected for two other genes and hybridization with
two probes resulted in a smear, probably due to the presence
of repeat sequences (data not shown). Using a set of Ad5- and
Ad12-transformed clonal cell lines, consistent di¡erential ex-
pression of one of the ¢ve genes was found (Fig. 1C).
The detection of only one consistently di¡erentially ex-
pressed gene is surprising as several genes have been reported
to be di¡erentially expressed in Ad5- versus Ad12-trans-
formed cells. Of the di¡erentially expressed genes, MHC I
[4], p90rsk1 [10] and JunB [11] ESTs were present on the ¢lter.
However, not all ESTs turned out to have the correct se-
quence. In the course of various array projects in our labora-
tory, we resequenced 47 ESTs used for the human I version
1.2 Gene Discovery Array and found that the sequence of 15
ESTs was completely di¡erent from the indicated sequences,
showing the low reliability of the given EST sequences. For
two additional ESTs of the set of 47 ESTs, clones were ob-
tained that consisted of mixtures of two di¡erent plasmids.
The sequences that were determined for the insert of these
plasmids also di¡ered from the sequences given by Incyte
Genomics. Thus the overall reliability of this set of ESTs
was 64%. Nevertheless, we paid special attention to the
ESTs that could be expected to show a di¡erence in Ad5-
and Ad12-transformed cells. One EST corresponding to
MHC class I was found to be indeed di¡erentially regulated
in the micro array analysis (data not shown), but the di¡er-
ence in expression was rather weak, which explains why we
had ignored this EST. A weak p90rsk1 signal was detected for
both cell lines of comparable intensity (data not shown). At
the position of the JunB-corresponding EST, as indicated by
Incyte Genomics, no signal was detected. Many of the regu-
latory proteins like kinases and transcription factors, are
known to be expressed at very low levels [12]. The fact that
for the mRNA of the transcription factor JunB no signal
could be detected and for the kinase p90rsk1 only a weak
signal was found, combined with the ¢nding that on average
a signal could be detected for only 10% of the ESTs (Fig. 1A),
indicates a rather low overall sensitivity of the assay. This is a
general problem for micro arrays, also when glass slides are
used instead of nylon ¢lters [13].
The di¡erentially expressed gene that we found corresponds
to EST58 (our nomenclature). A probe derived from this EST
detected signi¢cantly lower mRNA levels in Ad5-transformed
HER cell lines than in Ad12-transformed HER cell lines (Fig.
1C). Compared to non-immortal HER cells and an SV40-
transformed HER cell line, expression of the gene correspond-
ing to EST58 was decreased in Ad5-transformed HER cell
lines and, assuming constant GAPDH levels, increased in
Ad12-transformed HER cell lines. Decreased expression was
also found in Ad5-transformed HEL and HEK cell lines,
compared to non-immortal cells (Fig. 1D). We have been
unable to transform these cell types with the E1 region of
Ad12. However, non-immortal HEK cells have been trans-
formed with a hybrid construct containing Ad5E1A and
Ad12E1B. Expression of EST58-corresponding mRNA is still
signi¢cantly lower in this cell line compared to non-immortal
cells, although not as low as in the Ad5-transformed cell line.
This suggests a role for Ad5E1A in the process of downregu-
lation of the EST58 gene (Fig. 1D).
3.2. EST58 corresponds to the gene encoding FRP
According to the sequence information of Incyte Genomics,
EST58 is W52072. We resequenced this EST and found that
its sequence was completely di¡erent. A BLAST search did
not reveal any homology to other sequences deposited in Gen-
Bank [14]. Later on during this project, several other ESTs
with overlapping sequences were identi¢ed in GenBank and
subsequently obtained. The 5P and 3P parts of these ESTs were
sequenced (Fig. 2) and the sequence of the 5P 2180 bp of
AI690397 is deposited in GenBank (accession number
AF288537). An open reading frame was found in the most
5P part of AI690397 which was identical to the overlapping
sequence of the gene encoding the FRP [15]. Tanaka et al.
have published an independently isolated clone, which was
named follistatin like-1 (FSTL-1) [16]. FSTL-1 di¡ers from
our sequence and from the published FRP sequence in the
3P part of the untranslated region. Searching the human ge-
nome database revealed that only this part of the FSTL-1
sequence maps to chromosome 7, whereas sequence-tagged
sites of FRP and EST58 map to chromosome 3. This indicates
that the published FSTL-1 sequence might be derived from a
hybrid cDNA originating from FRP and a second transcript.
The conclusion is that the gene corresponding to EST58 is frp.
Fig. 2. Sequence analysis of EST58 and overlapping ESTs. EST58
and the underlined parts of ESTs AI690397 and AI866922 were se-
quenced. These sequences were completely identical to the overlap-
ping sequence of the gene encoding the FRP and partially identical
to the overlapping sequence of the gene encoding FSTL-1. Hatching
indicates identical overlapping sequences. The gray box indicates the
part of FSTL-1 that di¡ered from our overlapping sequence and the
overlapping sequence of FRP. Asterisks indicate parts of ESTs that
have not been sequenced.
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Consistently, rehybridization of the Northern blots of Fig. 1
with a 5P probe from clone AI690392 gave identical results
(data not shown).
3.3. Expression of FRP in normal and transformed tissues
To study the expression levels of FRP in normal human
tissues, a multiple-tissue Northern blot was hybridized with
a probe corresponding to the 3P end of FRP (Fig. 3A). For
most tissues, a single transcript was detected of approximately
4 kb and upon prolonged exposure, an additional longer tran-
script was detected. FRP was highly expressed in heart (lane
2) and placenta (lane 10), low expression was found in colon
(lane 4), thymus (lane 5) and spleen (lane 6) and no expression
could be detected in brain (lane 1) and peripheral blood leu-
kocytes (lane 12). These results are largely similar to those of
Tanaka et al., except that they do detect expression of FRP in
the human brain [16].
Since Ad12 transformation has been shown to be a suitable
model for oncogenic transformation, we studied whether FRP
expression is also deregulated in human tumors. Upon hybrid-
ization of Northern blots with the FRP cDNA probe de-
scribed above, a signi¢cant increase in FRP expression in
Wilms tumors compared to primary kidney tissue was ob-
served in ¢ve out of ¢ve patients (Fig. 3B).
It has been suggested that FRP functions as a TGF-L an-
tagonist [17]. This hypothesis is mainly based on the presence
of a domain that was previously found in follistatin, an in-
hibitor of the TGF-L family members activin and BMPs [18].
Contrary to this hypothesis, FRP has been found to have no
e¡ect on the growth-inhibitory action of TGF-L1 on CCl-64
cells [15]. Furthermore, it does not bind to TGF-L1, BMP4 or
BMP7 [19]. Clearly, a better understanding of the biological
function of FRP will be necessary to determine which role
FRP may have in Ad transformation.
3.4. FRP expression correlates with factor binding to SBE
FRP was originally identi¢ed as a TGF-L-regulated gene
[17]. Therefore, the di¡erence in FRP expression between
Ad5- and Ad12-transformed HER cell lines might be ex-
Fig. 3. mRNA levels of FRP in normal and transformed tissues.
A: A multiple-tissue Northern was hybridized with a [K-32P]dCTP
labeled 0.8 kb NotI^EcoRI EST58 fragment. As a control for equal
loading, the expression of L-actin was determined. B: FRP mRNA
is upregulated in Wilms tumors. Total RNA was isolated from
Wilms tumors (T) and corresponding normal kidney tissue (N).
Equal amounts of total RNA were size-fractionated and transferred
to Hybond ¢lters. These ¢lters were hybridized with a [K-32P]dCTP
labeled 0.8 kb NotI^EcoRI EST58 fragment. Control hybridizations
were performed using the PstI fragment of the rat GAPDH cDNA.
Fig. 4. EMSA for binding of Ad5- and Ad12 nuclear proteins to
SBE. A: Nuclear extracts of TGF-L1-treated (lanes 2, 4, 7 and 9)
or untreated (lanes 1, 3, 5, 6 and 8) exponentially growing Ad5-
HER clone 1 (lanes 1 and 2), ^ clone 2 (lanes 3 and 4), Ad12-HER
clone 6 (lane 5) ^ clone 7 (lanes 6 and 7) and HEPG2 cells (lanes 8
and 9) were incubated with a double-stranded oligo containing three
SBE. TGF-L1-induced complexes are indicated. The speci¢city of
this band is shown in (B), where nuclear extracts of untreated expo-
nentially growing Ad12-HER clone 7 were incubated with the la-
beled probe as described in (A, lane 1) in the presence of cold spe-
ci¢c (s) competitor (lane 2) or a-speci¢c (a) competitor (lane 3).
FEBS 24431 27-12-00
A.C.O. Vertegaal et al./FEBS Letters 487 (2000) 151^155154
plained by a di¡erence in TGF-L signaling between these cell
lines. TGF-L binds to its receptor, which leads to phosphor-
ylation and thereby activation of Smad, which subsequently
translocate to the nucleus and activate transcription of target
genes by binding to SBE in the promoters of these genes [18].
To test whether Ad5- and Ad12-transformed HER cell lines
di¡er in their factor binding activity to SBE, an EMSA was
carried out (Fig. 4A). In untreated Ad5-transformed HER
cells and in control HepG2 cells [20], a signal is hardly visible
at the position of the retarded band induced by TGF-L (Fig.
4, lanes 1^4, 8 and 9). In contrast, in Ad12-transformed HER
cell lines (lanes 5 and 6) a strong retarded band is already
present in the absence of TGF-L stimulation (lanes 5 and 6),
which is further induced by TGF-L treatment (lane 7 versus
6). Therefore, in Ad12-transformed HER cell lines a constitu-
tive binding activity to SBE is present. This binding activity is
speci¢c for the SBE elements, since it can be competed with a
33-fold molar excess of unlabeled wild-type SBE probe, but
not with unlabeled mutant SBE probe (Fig. 4B). The mecha-
nism leading to enhanced factor binding is presently not
known. An obvious explanation of constitutive expression of
active TGF-L forms by Ad12-transformed cells turned out to
be unlikely as both Ad5- and Ad12-transformed HER cells
secrete inactive TGF-L that upon activation by heat treatment
has a comparable activity (data not shown). Also the signi¢-
cance of binding activity to SBE in Ad12-transformed cells is
not known, but it is reasonable to assume that it will lead to a
di¡erential expression of genes normally regulated by the
TGF-L family. This di¡erential gene expression might well
contribute to the di¡erences in oncogenic behavior of Ad5-
and Ad12-transformed cell lines, as the TGF-L factors are
known to play essential roles in growth and development [18].
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